Navigation Links
VIA Pharmaceuticals Set to Join Russell Microcap Index
Date:6/27/2008

ome cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting on our be
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
5. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
6. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
7. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
8. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
9. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... , May 28, 2015 Natera, Inc., ... a study published in Ultrasound in Obstetrics ... polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify ... A study based upon data ... pregnancies occur in about 1 in 1,000 pregnancies, ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2
... , CARLISLE, Mass., Aug. 5 ... launch of a fully integrated microarray solution platform. ... biochips and advanced microarray instrument systems, in collaboration ... and instrumentation software, now offers a platform that ...
... , CHICAGO, Aug. 5 Advanced ... it will host a conference call and webcast discussing the Company,s ... a.m. (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, ... present an update on the Company. A press release reporting the ...
... Framework Reaffirmed , Shire plc (LSE: SHP, NASDAQ: SHPGY ) the global specialty,biopharmaceutical company, announces results for the ... ... Q2 2009(1), Product sales ... -21%, Product sales (excluding ADDERALL XR) $491 million ...
Cached Biology Technology:CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 2CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 3Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 3Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 4Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 5Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 6Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 7Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 8Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 9Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 10Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 11Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 12Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 13Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 14Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 15Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 16Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 17Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 18Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 19Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 20Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 21Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 22Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 23Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 24Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 25Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 26Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 27Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 28Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 29Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 30Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 31Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 32Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 33
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Ky. The University of Louisville today announced that ... into a license and research collaboration agreement with Novartis ... the potential to help transplant patients avoid taking anti-rejection ... for treatment of other diseases. The University ...
... Boston University School of Medicine (BUSM) suggests that epigenetics may ... relapse of cancer. The findings are published online in Volume ... The term epigenetics refers to the external modifications ... do not change the DNA sequence, but instead, they affect ...
... MA New insights into how human cytomegalovirus ... with infection spreads from pregnant mother to fetus ... translational researchers an exciting new avenue for investigation ... interventions. Using next generation sequencing and population genetic ...
Cached Biology News:University of Louisville researchers sign global licensing agreement 2University of Louisville researchers sign global licensing agreement 3BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy 2Research points to potential window for treating CMV and preventing mother-to-child transmission 2Research points to potential window for treating CMV and preventing mother-to-child transmission 3
... Designed to meet the ... this animal component-free medium supports ... high cell densities, while maintaining ... recombinant protein production using the ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z36,327-8) ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: